Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 6, 2020

Primary Completion Date

May 10, 2021

Study Completion Date

June 8, 2021

Conditions
CoronaVirus Induced Disease-2019 (COVID-19)
Interventions
DRUG

Ibrutinib

Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.

DRUG

Placebo

Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.

Trial Locations (9)

20037

Duplicate_GW Medical Faculty Associates /ID# 222023, Washington D.C.

33136

University of Miami /ID# 223227, Miami

34982

Midway Immunology and Research /ID# 222004, Ft. Pierce

84103

Intermountain Healthcare /ID# 221955, Salt Lake City

94305-2200

Stanford University School of Med /ID# 221954, Stanford

20010-3017

Medstar Washington Hospital Center /ID# 221886, Washington D.C.

33407-3100

Triple O Research Institute /ID# 222944, West Palm Beach

02115

Brigham & Women's Hospital /ID# 221847, Boston

02215-5400

Beth Israel Deaconess Medical Center /ID# 222994, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen Research & Development LLC; Pharmacyclics LLC (An AbbVie Company)

UNKNOWN

lead

AbbVie

INDUSTRY